Stereotaxis released initial clinical results supporting its MAGiC robotic magnetic navigation catheter in the Journal of Interventional Cardiac Electrophysiology. The multi-center, single-arm study showed a 94% acute procedural efficacy rate and a low 1.5% adverse event rate among 67 patients treated for various arrhythmias, including AFib, VT, and WPW syndrome.
MAGiC combines robotic magnetic navigation with radiofrequency ablation, aiming to improve safety, efficacy, and physician control. The catheter received CE mark clearance in January and was submitted to the FDA in March. Enrollment continues with around 100 patients to be evaluated over one year.
“We are excited by these results as we expand MAGiC’s presence in Europe,” said CEO David Fischel.
Follow MEDWIRE.AI for the latest in electrophysiology innovation and clinical research.
